An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

  • Cancer
  • Non Hodgkin Lymphoma (NHL)
  • Lymphoma
  • Leukemia
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Cities
  • Ansan-si
  • Anyang
  • Bucheon
  • Busan
  • Daegu
  • Daejeon
  • Gwangju
  • Incheon
  • Seoul
  • Suwon
  • Ulsan
  • Yangsan
Trial Identifier:

NCT03289182 ML39600

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a prospective, multicenter, non-interventional study to test the safety and effectiveness of MabThera administered subcutaneously in participants with NHL or CLL. The length of study is expected to be 6 years.

      Hoffmann-La Roche Sponsor
      N/A Phase
      NCT03289182, ML39600 Trial Identifier
      MabThera Treatments
      Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell Condition
      Official Title

      Post-Marketing Surveillance of MabThera Subcutaneous in Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

      Eligibility Criteria

      All Gender
      ≥ 19 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participants administered with MabThera subcutaneously within the approved indication in Korea
      • Participants previously untreated with MabThera subcutaneously

      Inclusion Criteria for NHL participants for MabThera subcutaneously 1400mg:

      • Relapsed or chemoresistant follicular lymphoma (FL) (B, C, and D type by international working formulation classification of B-cell NHL) participants
      • Previously untreated FL participants in combination with chemotherapy
      • Participants who are treated with maintenance therapy after the treatment of FL participants responding to induction therapy.
      • Cluster of differentiation 20-positive, diffuse large B-cell NHL participants in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone (8 cycles) chemotherapy

      Inclusion Criteria for CLL participants for MabThera subcutaneously 1600mg:

      • Previously untreated or relapsed/refractory CLL participants in combination with chemotherapy
      Exclusion Criteria
      • Pregnant or breastfeeding women
      • Participants who are out of locally approved indications, dosage, and administration including medication error
      • Contraindication in use by locally approved indications, dosage, and administration

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Lymphoma Leukemia

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now